Valuation: Jubilant Pharmova Limited

Capitalization 159B 1.66B 1.43B 1.3B 1.23B 2.29B 2.3B 15.56B 6.04B 75.61B 6.24B 6.11B 263B P/E ratio 2026 *
-
P/E ratio 2027 * 28.8x
Enterprise value 159B 1.66B 1.43B 1.3B 1.23B 2.29B 2.3B 15.56B 6.04B 75.61B 6.24B 6.11B 263B EV / Sales 2026 *
1.94x
EV / Sales 2027 * 1.72x
Free-Float
35.51%
Yield 2026 *
0.41%
Yield 2027 * 0.5%
1 day+0.92%
1 week+5.17%
Current month+8.39%
1 month+12.59%
3 months+10.06%
6 months-10.78%
Current year-6.54%
1 week 970.6
Extreme 970.6
1,030.95
1 month 893.45
Extreme 893.45
1,030.95
Current year 783.75
Extreme 783.75
1,106.9
1 year 783.75
Extreme 783.75
1,250
3 years 318.5
Extreme 318.5
1,309
5 years 268.8
Extreme 268.8
1,309
10 years 230
Extreme 230
1,309
Manager TitleAgeSince
Chief Executive Officer 39 2023-05-31
Chief Executive Officer 49 2023-05-31
Director of Finance/CFO 59 2025-09-30
Director TitleAgeSince
Chairman 73 1978-07-20
Chairman 69 2012-08-01
Director/Board Member 76 2017-05-22
Change 5d. change 1-year change 3-years change Capi.($)
+0.92%+5.17%+10.61%+194.57% 1.65B
-0.89%+3.19%+40.60%+131.55% 906B
-0.11%+3.49%+57.33%+44.32% 555B
+1.18%+4.02%+18.83%+43.84% 368B
-0.94%-2.05%+21.74%+10.73% 326B
-0.19%+3.20%+37.10%+14.50% 289B
+0.78%+1.00%+29.63%+26.23% 285B
-0.38%+0.74%+53.98%-2.78% 280B
+0.91%+2.12%-31.78%-49.10% 208B
+0.09%+2.48%+28.58%+44.41% 182B
Average +0.14%+1.40%+26.66%+45.83% 340.01B
Weighted average by Cap. -0.14%+1.25%+33.97%+50.72%

Financials

2026 *2027 *
Net sales 82.15B 859M 736M 673M 637M 1.18B 1.19B 8.03B 3.12B 39.04B 3.22B 3.16B 136B 92.59B 968M 830M 759M 718M 1.33B 1.34B 9.05B 3.52B 44B 3.63B 3.56B 153B
Net income 4.08B 42.66M 36.55M 33.42M 31.65M 58.59M 59.06M 399M 155M 1.94B 160M 157M 6.75B 5.51B 57.65M 49.39M 45.16M 42.76M 79.17M 79.81M 539M 209M 2.62B 216M 212M 9.12B
Net Debt - -
Logo Jubilant Pharmova Limited
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company’s segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services, and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
Employees
5,547
Date Price Change Volume
26-05-14 1,004.50 +0.92% 3,660
26-05-13 995.35 +0.33% 9,865
26-05-12 992.10 -0.48% 8,388
26-05-11 996.85 -1.16% 16,622
26-05-08 1,008.60 +2.79% 12,177
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1,004.50INR
Average target price
1,312.50INR
Spread / Average Target
+30.66%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. 530019 Stock